Vinflunine - An active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: Results of a phase II study

British Journal of Cancer

Volumn 94, Issue 10, 2006, Pages 1383-1388

  Bennouna, J ^a   Breton, J L ^b   Tourani, J M ^c   Ottensmeier, C ^d   O'Brien, M ^e   Kosmidis, P ^f   Huat, T E ^g   Pinel, M C ^h   Colin, C ^h   Douillard, J Y ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Centre Hospitalier General   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f HYGEIA HOSPITAL   (Greece)

^g DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Non small cell lung cancer; Phase II study; Vinflunine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LAXATIVE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; VINBLASTINE; VINFLUNINE;

ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NEUROPATHIC PAIN; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; SURVIVAL RATE; VINBLASTINE;

EID: 33646831647     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603106     Document Type: Article

References (25)

1. American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 15: 2996-3018
2. Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM, Puozzo C, Marty ML (2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours Ann. Ann Oncol 14: 630-637
3. Biesma B, Smit EF, Postmus PE (1999) A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small-cell lung cancer after platinum containing chemotherapy. Lung Cancer 24: 115-121
4. Dancey J, Shepherd F, Ramlau R, Mattson K, Gressot L, O'Rourke M, Vincent M, Burkes R, Levitan N, Bergman B, Baez L, Rudd R, Kim Y, Coughlin S, Soussan-Lazard K, Gralla R (1999) Quality of life (QOL) assessment in a randomised study of taxotere (TAX) vs best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum based chemotherapy. Proc Am Soc Clin Oncol 18: 491 (abstract 1896)
5. Etiévant C, Kruczynski A, Chansard N, Cabrol N, Astruc J, Chazottes E, Hill BTL (1998) Characterization of apoptosis induced by vinflunine, a novel fluorinated vinca alkaloid, in sensitive and vinflunine resistant P388 tumor cells: concomitant cell cycle analysis. Proc Am Assoc Cancer Res 39: 166
6. Fahy J, Duflos A, Ribet JP, Jacquesy JC, Berrier C, Jouannetaud MP, Zunino F (1997) Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 36: 8576-8577
7. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
8. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V; Lee JS, Moore M, Gandara D, Karp K, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Phase III trial of docetaxel vs vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362
9. Green S, Weiss GR (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253
10. Hanna N, Shepherd FA, Fossella FV, Pereira JR, Marinis P, Pawel JV, Gatzemeier U, Muller T, Tsao CY, Pless M, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn Jr PA (2004) Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597
11. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A (1999) Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 35: 512-520
12. Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized phase III trial of paclitaxel plus carboplatin vs vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218
13. Kruczynski A, Astruc J, Ricome C, Colpaert F, Hill BT (1999) Definite antitumour activity of vinflunine, a novel fluorinated vinca alkaloid, against human tumour xenografts. Contrib Oncol Basel, Karger 54: 369-378
14. Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel vinca alkaloid. Biochem Pharmacol 55: 635-648
15. Lobert S, Ingram JW, Hill BT, Correia JJ (1998) A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53: 908-915
16. Miller V, Fossella F, DeVore R, Kerr R, Crawford J, Karp D, Vokes E, Levitt M, Kim Y, Rodgers A, Hammershaimb L, Gamza F (1999) Docetaxel (D) benefits lung cancer symptoms and quality of life (QOL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum based therapy. Proc Am Soc Clin Oncol 18: 491 (abstract 1895)
17. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MAL (2001) Mechanism of mitotic block and inhibition of cell proliferation by semisynthetic vinca alkaloids vinorelbine and its new derivative vinflunine. Mol Pharmacol 60: 225-232
18. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson LL (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60: 5045-5051
19. Rosvold E, Langer CJ, Schilder R, Milenson M, Reimet E, Kreamer K (1998) Salvage therapy with gemcitabine in advanced non-small-cell lung cancer (NSCLS progressing after prior carboplatin-paclitaxel). Proc Am Soc Clin Oncol 17: 467a (abstract 1797)
20. Schiller JH, Harrington D, Belani C, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98
21. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel vs best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103
22. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, Van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
24. Vansteenkiste JF, Breton JL, Sandler A, Lara P, Paz-Ares L, Bonomi P, Le Chevalier T, Ardizzoni A, Peck R, Edelman M (2003) A randomised phase II study of epothilone analogue BMS-247550 in patients with non-small cell lung cancer who have failed first-line platinum-based chemotherapy. ProcAm Soc Clin Oncol 22: A2519
25. WHO Handbook for reporting results of cancer treatment, Geneva: World Health Organisation, 1979